BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Maximizing the Potential of Radiopharmaceuticals through Novel
  Targets\, Expanded Isotopes and Supply\, and Enhanced Dosimetry to Drive
  Efficacious Therapies From Bench to Approval.\n\nRadiopharmaceuticals ar
 e no longer an emerging promise\, they are becoming a defining force in o
 ncology. Once considered a niche modality\, targeted radiopharmaceutical 
 therapies are rapidly moving into the spotlight as one of the most promis
 ing approaches for precision cancer treatment. With major pharmaceutical 
 companies investing heavily\, pipelines expanding at pace\, and clinical 
 successes demonstrating the power of targeted radiation delivery\, the fi
 eld is transitioning from early validation to scale.\n\nMomentum across t
 he sector is undeniable. Breakthrough therapies continue to advance throu
 gh the clinic\, alpha-emitting isotopes are unlocking new possibilities f
 or highly potent tumour targeting\, and the theranostic paradigm is redef
 ining how patients are diagnosed and treated. As more assets progress int
 o late-stage trials and combination strategies gain traction\, radiopharm
 aceuticals are positioned to play a central role in the next generation o
 f oncology therapeutics.\n\nYet with this rapid growth comes a unique and
  complex set of challenges. Unlike traditional drug modalities\, radiopha
 rmaceutical development requires a tightly integrated ecosystem spanning 
 isotope production\, radiochemistry\, manufacturing infrastructure\, spec
 ialized clinical sites\, and regulatory expertise.\n\nThis is why the 5th
  Targeted Radiopharmaceuticals Summit US returns in 2026 as the industry'
 s most comprehensive end-to-end meeting dedicated to advancing radioligan
 d therapies from discovery through to commercialization. Taking place Jul
 y 21–23\, 2026 in San Diego\, California\, the summit will bring together
  260+ leaders from across the radiopharmaceutical field\, including bioph
 arma innovators\, nuclear medicine physicians\, radiochemists\, isotope s
 uppliers\, CDMOs\, regulators\, and investors\, to tackle the scientific\
 , clinical\, and operational challenges shaping the field.\n\nOver three 
 days of technical discussions\, strategic insights\, and collaborative ne
 tworking\, attendees will explore the full lifecycle of targeted radiopha
 rmaceutical development\, from discovery and preclinical innovation throu
 gh clinical translation\, manufacturing scale-up\, and supply chain resil
 ience.\n\nWhether you are developing the next generation of radioligand t
 herapies\, building isotope production capacity\, advancing clinical tria
 ls\, or supporting the infrastructure needed to bring these therapies to 
 patients\, the 5th Targeted Radiopharmaceuticals Summit US is where the c
 ommunity comes together to move the field forward. Join the experts shapi
 ng the future of targeted radioligand therapy and help define the next ch
 apter of precision oncology.\n\n&nbsp\;\n\nDate and Time: On Tuesday July
  21\, 2026 at 8:00 am to Thursday July 23\, 2026 at 6:00 pm\n\nVenue deta
 ils: San Diego Marriott La Jolla\, 4240 La Jolla Village Drive\, La Jolla
 \, California\, 92037\, United States\n
DTEND:20260723T180000
DTSTAMP:20260512T220025Z
DTSTART:20260721T080000
LOCATION:San Diego Marriott La Jolla\, 4240 La Jolla Village Drive\, La Jo
 lla\, California\, 92037\,
SEQUENCE:0
SUMMARY:Maximizing the Potential of Radiopharmaceuticals through Novel Tar
 gets\, Expanded Isotopes and Supply\, and Enhanced Dosimetry to Drive Eff
 icacious T...
UID:f10d80f2-fe27-4e43-a405-6196a1526b3b
END:VEVENT
END:VCALENDAR